Stocks · News reference

Chemours shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $29 to $18.

Aug 10, 2026, 4:19 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 8, 2026, 8:34 AMBenzinga Insights
Chemours Q2 2026 Earnings Call: Complete Transcript
Chemours (NYSE:CC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
CC
BenzingaOct 5, 2026, 7:58 PMBenzinga Newsdesk
UBS Maintains Neutral on Chemours, Lowers Price Target to $16
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.
CC
BenzingaSep 30, 2026, 1:30 PMBenzinga Newsdesk
Mizuho Maintains Outperform on Chemours, Lowers Price Target to $18
CC
BenzingaSep 10, 2026, 4:26 PMAkanksha Bakshi
Why Is Chemours Stock Trading Higher Today?
Chemours PFAS settlement lifts shares as the $455 million deal clarifies liabilities, payment timing and future escrow obligations.
CC CTVA DD